Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867008063822626816 |
|---|---|
| author | Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling |
| author_facet | Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling |
| collection | Wiley Open Access |
| contents | Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling Journal of Clinical Apheresis ABSTRACT Plerixafor (PLX) is FDA approved for use in autologous peripheral blood stem cell donors but not in allogeneic donors. This study was completed by members of the ASFA HPC Donor Subcommittee to examine the incidence and characteristics of poor mobilizers (PM) among matched related donors (MRD), as well as factors associated with PLX use in MRD. Risks of poor mobilization in MRD were older age, especially donors older than 60 years, lower baseline platelet counts, and heavier recipients. PLX use in PM was low but safe, tripling the success rate for collection. This study adds evidence to the body of literature to support use of PLX in allogeneic donors who are PM. 10.1002/jca.70074 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/jca.70074 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_jca_70074 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling Journal of Clinical Apheresis Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors Elizabeth A. Godbey Nicole L. Draper Laura Connelly‐Smith Caroline Alquist Joseph Schwartz Leonor Fernando Andrew Jones Amy E. Schmidt Charles Harmon Esther Lee Yevgeniy Linnik Laura Cooling Journal of Clinical Apheresis ABSTRACT Plerixafor (PLX) is FDA approved for use in autologous peripheral blood stem cell donors but not in allogeneic donors. This study was completed by members of the ASFA HPC Donor Subcommittee to examine the incidence and characteristics of poor mobilizers (PM) among matched related donors (MRD), as well as factors associated with PLX use in MRD. Risks of poor mobilization in MRD were older age, especially donors older than 60 years, lower baseline platelet counts, and heavier recipients. PLX use in PM was low but safe, tripling the success rate for collection. This study adds evidence to the body of literature to support use of PLX in allogeneic donors who are PM. 10.1002/jca.70074 http://creativecommons.org/licenses/by/4.0/ |
| title | Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors |
| topic | Journal of Clinical Apheresis |
| url | https://onlinelibrary.wiley.com/doi/10.1002/jca.70074 |